Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01
Recruiting · NCT07290894 · Registry updated 2026-04-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Pembrolizumab Plus Lenvatinib in Vulvar Cancer Patients: MITO VULVA-01 | Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, female reproductive system disorder, female reproductive system neoplasm, neoplasm, vulva cancer, vulvar disease | Recruiting | Phase 2 | 2026-04-02 | NCT07290894 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| National Cancer Institute, Naples | 38 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Nation Cancer Institute of Naples, Division of Medical Oncology - Uro-Gynecology Department, Naples | Naples | Italy | 1 |